Tirzepatide use for weight loss leads to severe euglycemic ketoacidosis with neurological deficits and renal failure
Background
Euglycemic ketoacidosis (EuDKA) is a known complication of SGLT-2 inhibitors, but its incidence is rising with GLP-1/GIP receptor agonists like tirzepatide. This condition presents a significant diagnostic challenge, particularly in patients with altered consciousness and unclear medical histories, as blood glucose levels remain normal. The mechanism often involves profound appetite suppression leading to starvation-induced ketosis, exacerbated by the drug's effects. Understanding this emerging risk is crucial for patient safety, especially given the increasing off-label use of these compounds for weight loss.
Study Design
This case report details a young woman, without pre-existing diabetes or obesity, who self-administered tirzepatide for aesthetic weight reduction. She presented with marked appetite suppression and reduced food intake, leading to severe symptoms. The diagnostic process involved evaluating her profound metabolic derangements and neurological status to identify the underlying cause. The patient's clinical course was closely monitored in an intensive care setting, with interventions aimed at correcting metabolic acidosis and supporting renal function, including advanced life support measures.
Results
The patient developed severe starvation-induced euglycemic ketoacidosis secondary to tirzepatide use. This manifested as profound metabolic acidosis, acute renal failure, and transient neurological deficits. Despite normal blood glucose levels, her condition was critical, necessitating intensive care admission. > The patient required continuous renal replacement therapy (CRRT) to manage the severe acute renal failure and metabolic derangements. This presentation was noted as unique and severe compared to previously reported cases of tirzepatide-induced EuDKA, highlighting the potential for extreme adverse outcomes even in individuals without traditional risk factors for ketoacidosis.
Key Findings
- Tirzepatide use for weight loss caused severe euglycemic ketoacidosis in a non-diabetic patient.
- Patient developed profound metabolic acidosis and acute renal failure.
- Transient neurological deficits were observed as a severe complication.
- Intensive care admission and continuous renal replacement therapy were required.
Why It Matters
This case underscores the critical importance for clinicians to maintain a high index of suspicion for euglycemic ketoacidosis in patients using tirzepatide, even with normal blood glucose levels. The severe presentation, including neurological deficits and acute renal failure, highlights the significant risks associated with off-label or unsupervised use of potent metabolic agents for aesthetic purposes. Peptide users and biohackers must be aware that profound appetite suppression can trigger dangerous metabolic states, especially when combined with drugs like tirzepatide. This emphasizes the need for careful medical evaluation and monitoring when using such compounds, and the potential for severe, life-threatening complications.